

# CHEMO PHARMA LABORATORIES LTD

**Registered Office:** 5-Kumud Apartment Co. Op. HSG. SOC. Ltd, Karnik Road, Chikan Ghar,  
Kalyan, Dist. Thane – 421301

---

Corporate Office: Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400001

---

Tel No.:022-22078382 [CIN: L99999MH1942PLC003556] PAN: AAACC2056K

Website: [www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)

Email : [chemopharmalaboratorieslimited@gmail.com](mailto:chemopharmalaboratorieslimited@gmail.com)

---

Date: August 12, 2025

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services,  
25th Floor, P. J. Towers, Dalal Street,  
Mumbai-400001

**Script Id: 506365**

**ISIN: INE320M01019**

**Subject: Outcome of Board Meeting held on Tuesday, August 12, 2025.**

Dear Sir / Madam,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Tuesday, **August 12, 2025** at the Registered Office of the Company, inter alia, have discussed the following matters:

1. Approved the Un-Audited Financial Results of the Company for the quarter ended June 30, 2025 along with the Limited Review Report thereon.
2. Approved the Notice of the 83<sup>rd</sup> Annual General Meeting of the members of the Company to be held on Wednesday, 24<sup>th</sup> September, 2025 at 4:00 P.M. for the year ended March 31, 2025.
3. Approved the Book Closure date from September 17, 2025 to September 24, 2025 (both days inclusive) and Record Date will be September 16, 2025 for the forthcoming Annual General Meeting of the Company.
4. Decided to change of Name of the Company from “Chemo Pharma Laboratories Limited” to any other suitable name to reflect new activities of the Company more dominantly and as may be available on MCA.
5. Decided to consider the the Main Object of the Company & alteration in Object Clause of Memorandum of Association of the Company. The Company is planning to venture into wholesale trading activities & commodity trading and accordingly a suitable amendment is to be made in Main Object of the Company.
6. Decided to shift the Registered Office of the Company from the State of Maharashtra (Kalyan) to State of Gujarat (Ahmedabad).
7. Appointment of CS Arvind Sudra, Proprietor of Arvind Sudra & Associates, Practicing Company Secretaries, to act as Scrutinizer for E-Voting at the forthcoming 83<sup>rd</sup> Annual General Meeting of the Company.

# CHEMO PHARMA LABORATORIES LTD

**Registered Office:** 5-Kumud Apartment Co. Op. HSG. SOC. Ltd, Karnik Road, Chikan Ghar,  
Kalyan, Dist. Thane – 421301

---

Corporate Office: Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400001

---

Tel No.:022-22078382 [CIN: L99999MH1942PLC003556] PAN: AAACC2056K

Website: [www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)

Email : [chemopharmalaboratorieslimited@gmail.com](mailto:chemopharmalaboratorieslimited@gmail.com)

---

The meeting commenced at 4 PM and concluded at **6:45 PM.**

The same may please be taken on record.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

Mehta Ruchit P.

RUCHIT MEHTA

Managing Director & Chief Executive Officer

DIN: 08810586





**Independent Auditor, Review Report on Unaudited Standalone Financial Results for the quarter and year to date of CHEMO PHARMA LABORATORIES LTD pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 (2) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended.**

To,  
The Board of Directors,  
**Chemo Pharma Laboratories Limited**

1. We have reviewed the accompanying statements of unaudited IND-AS Financial Results of **CHEMO PHARMA LABORATORIES LTD** ("the Company") for the quarter ended 30<sup>th</sup> June, 2025 ("The Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Director's, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in compliance with Listing Obligations. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SSRV & Associates  
Chartered Accountants  
Firm Reg. No.: 135901W



**Vishnu Kant Kabra**  
Partner  
M. No.: 403437  
Place: Mumbai  
Date: 12<sup>th</sup> August, 2025  
UDIN: 25403437BMIPLB6516



**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025**

(Rupees in Thoudsand)

Sr. No	Particulars	Quarter ended			Year ended
		30th June 2025	31st March 2025	30th June 2024	31st March 2025
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations	0.00	0.00	0.00	0.00
II	Other income	207.12	(1641.00)	3018.00	6198.00
III	<b>TOTAL REVENUE</b>	<b>207.12</b>	<b>(1641.00)</b>	<b>3018.00</b>	<b>6198.00</b>
IV	<b>EXPENSES</b>				
	(1) Cost of materials consumed	0.00	0.00	0.00	0.00
	(2) Purchases of stock-in-trade	0.00	0.00	0.00	0.00
	(3) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00
	(4) Employee benefits expense	240.60	54.00	54.00	216.00
	(5) Finance costs	5.38	0.00	0.00	0.00
	(6) Depreciation and amortisation expense	0.00	14.00	14.00	54.00
	(7) Administrative & Other expenses	118011.79	129.00	484.00	948.00
	<b>TOTAL EXPENSES</b>	<b>118257.77</b>	<b>197.00</b>	<b>552.00</b>	<b>1218.00</b>
V	Profit/(Loss) before exceptional items & tax	(118050.65)	(1838.00)	2466.00	4980.00
VI	Exceptional items (net charge)	0.00	0.00	0.00	0.00
VII	Net Profit before ExtraOrdinaray Items & Tax	(118050.65)	(1838.00)	2466.00	4980.00
VIII	Extraordinary Items	0.00	0.00	0.00	0.00
IX	<b>Profit before Tax</b>	(118050.65)	(1838.00)	2466.00	4980.00
X	<b>Tax Expenses</b>				
	(1) Current tax	0.00	1993.00	0.00	1993.00
	(2) Tax Aduustment Previous Year	0.00	0.00	0.00	0.00
	(3) Deferred tax credit/(charge)	0.00	(435.00)	0.00	(435.00)
	(4) MAT Credit Entitlement	0.00	0.00	0.00	0.00
XI	<b>PROFIT/Loss FOR THE PERIOD from continious operations</b>	(118050.65)	(3396.00)	2466.00	3422.00
XII	PROFIT/Loss from dis-continious operations	0.00	0.00	0.00	0.00
XIII	Tax expenses for dis-continious operations	0.00	0.00	0.00	0.00
XIV	PROFIT/Loss FOR THE PERIOD from dis-continious operations	0.00	0.00	0.00	0.00
XV	<b>PROFIT/Loss FOR THE PERIOD</b>	(118050.65)	(3396.00)	2466.00	3422.00
XVI	<b>OTHER COMPREHENSIVE INCOME</b>				
	A(i)Items that will not be reclassified subsequently to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified subsequently to profit or loss	0.00	0.00	0.00	0.00
XVII	<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (Comprising Profit/(Loss) and other comprehensive income for the period</b>	(118050.65)	(3396.00)	2466.00	3422.00
XVIII	Earnings per equity share				
	(1) Basic	-78.70	-2.26	1.64	2.28
	(2) Diluted	-78.70	-2.26	1.64	2.28

FOR CHEMO PHARMA LABORATORIES LIMITED


Date: 12.08.2025

Place: Mumbai



*Mehta Ruchit*

RUCHIT MEHTA  
MD & CEO  
DIN: 08810586



**Notes:**

1. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies . (Indian Accounting Standard) Accounting Rules, 2016.
2. The above Standalone Unaudited Financial Results for the Quarter Ended 30.06.2025 have been reviewed by the Audit Committee in their Meeting held on 12.08.2025 and approved by the Board of Directors of its Meeting held on 12.08.2025. The Limited Review Report of Auditors M/s S S R V & Associates was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidiary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

**Rs. In Thousands**

PARTICULARS	STANDALONE		
	UNAUDITED QUARTER ENDED 30.06.2025	UNAUDITED QUARTER ENDED 30.06.2024	UNAUDITED QUARTER ENDED 31.03.2025
<b>Reconciliation of Profit After Tax as reported earlier:</b>			
Net Profit / (Loss) for the Period (as per AS)	-118050.65	964	-1837
Benefit / (Charge):			
Impact of Deferred Income (Government Grant) Amortized to Income	0	0	0
Impact of Fair Valuation of Financial Instruments	0	1502	1993
Impact of Actuarial Gain / Loss Taken OCI	0	0	0
Impact of Adjustment of Deferred Tax	0	0	-435
Impact of Adjustment of MAT Credit Entitlement	0	0	
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>-118050.65</b>	<b>2466</b>	<b>-3396</b>

FOR CHEMO PHARMA LABORATORIES LIMITED

Date: 12.08.2025

Place: Mumbai

*Mehta Ruchit R.*

RUCHIT MEHTA

MD &amp; CEO

DIN: 08810586



# CHEMO PHARMA LABORATORIES LTD

**Registered Office:** 5-Kumud Apartment Co. Op. HSG. SOC. Ltd, Karnik Road, Chikan Ghar,  
Kalyan, Dist. Thane – 421301

---

Corporate Office: Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400001

---

Tel No.:022-22078382 [CIN: L99999MH1942PLC003556] PAN: AAACC2056K

Website: [www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)

Email : [chemopharmalaboratorieslimited@gmail.com](mailto:chemopharmalaboratorieslimited@gmail.com)

---

Date: August 12, 2025

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services,  
25th Floor, P. J. Towers, Dalal Street,  
Mumbai-400001

**Script Id: 506365**

**ISIN: INE320M01019**

Subject: Intimation of Book Closure Pursuant to the Regulation 42(2) to (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

This is to inform you that Register of Members (Share Transfer Book) will be closed pursuant to the Regulation 42(2) to (4) of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 in connection to the Annual General Meeting (AGM) of the Company, which is going to be held on Wednesday, September 24, 2025. Details of dates are as follows –

1. Book Closure Date – September 17, 2025 to September 24, 2025 (both days inclusive)
2. Record Date – September 16, 2025

You are requested to take this on your records.

Thanking You.  
Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

*Mehta Ruchit P.*



RUCHIT MEHTA  
Managing Director & Chief Executive Officer  
DIN: 08810586